Selenium supplementation in radiotherapy patients: do we need to measure selenium levels in serum or blood regularly prior radiotherapy? by Ralph Muecke et al.
Muecke et al. Radiation Oncology 2014, 9:289
http://www.ro-journal.com/content/9/1/289LETTER TO THE EDITOR Open AccessSelenium supplementation in radiotherapy
patients: do we need to measure selenium levels
in serum or blood regularly prior radiotherapy?
Ralph Muecke1,2*, Oliver Micke3, Lutz Schomburg4, Klaus Kisters5, Jens Buentzel6, Jutta Huebner7 and Jan Kriz8Abstract
Considering the review by Puspitasari and colleagues, an additional discussion of the endpoints of the Se
supplementation studies described would be helpful. In our view, selenium can safely be given to selenium-deficient
cancer patients prior to and during radiotherapy. Therefore, in order to help the radiation oncologist in decision
making, we strongly advocate to determine the selenium status prior to and during a potential adjuvant selenium
supplementation, e.g. when trying to ease the side-effects of radiation treatment or in the aftercare situation when the
selenium status may become insufficient.
Keywords: Selenium, Supplementation, Clinical studies, Selenoproteins, RadiotherapyWe have read with great interest the review of Puspitasari
et al. and would like to thank the authors for this interest-
ing summary which shows the possible benefits of selen-
ium supplementation in radiotherapy patients reducing
side effects and thus improving quality of life without
compromising the effectiveness of radiotherapy [1].
In the introduction, the authors point to the necessity
of a guideline helping physicians and patients with their
decisions concerning selenium supplementation. They
correctly point to the lack of comprehensive data. Yet, if
one enlarges the range of their systematic search, there
are additional data which to our opinion could form the
basis of practice rules concerning selenium in cancer
care. In fact, there is a wealth of preclinical and clinical
data pointing to the dose-dependency of health effects
from selenium supplementation and the high mortality
risk of selenium-deficient cancer patients [2].
According to recently published studies it seems most
important for cancer patients to achieve and maintain a
certain range of Se in the serum. Nutritional Se intake,
plasma Se concentration and glutathione peroxidase
(GPx) activity display a positive correlation up to a* Correspondence: ralph.muecke@klinikum-lippe.de
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unless otherwise stated.certain threshold plasma Se concentration (70–100 μg/L),
beyond which the GPx activity plateaus [3]. The limit at
which selenoprotein P (SePP) concentrations may no lon-
ger increase with higher Se intake has been determined at
levels of around 90–125 μg Se/l plasma [4-6]. Conse-
quently, the optimal Se range in serum likely resides
between 100 and 130 μg/l [7,8]. This is in accordance with
epidemiological and clinical data which underline that
cancer and mortality risks inversely correlate to Se con-
centrations at suboptimal levels <100 μg Se/l plasma as
compared to higher Se status [9].
Considering the review by Puspitasari and colleagues,
an additional discussion of the endpoints of the Se sup-
plementation studies described would be helpful. In
order to determine effects from selenium basic and
follow-up levels need to be determined. Unfortunately,
some well-known and frequently cited allegedly negative
studies did not obey to these simple rules and it is thus
difficult to interpret their findings [10,11].
Therefore, in order to help the radiation oncologist in
decision making, we strongly advocate to determine the
selenium status prior to and during a potential adjuvant
selenium supplementation, e.g. when trying to ease the
side-effects of radiation treatment or in the aftercare
situation when the selenium status may become insuffi-
cient. The potential benefits for the cancer patient under
radiotherapy are well-documented and undisputed [1,2].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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http://www.ro-journal.com/content/9/1/289In our view, selenium can safely be given to selenium-
deficient cancer patients prior to and during radio-
therapy. Considering the known uncertainties around
the appropriate Se dose and Se compound we would
propose the inorganic form sodium selenite without un-
specific incorporation into non-selenoenzymes and daily
doses higher than in the above mentioned gynecological
study of 500 μg since the patients with Se supplementa-
tion did not achieve Se levels in the serum higher than
75 μg/l [12]. Finally we want to point out that selenium
is not a medication per se but rather an adjuvant treat-
ment option supporting the biosynthesis of 25 human
genes encoding the functionally active selenoproteins
needed for limiting the side effect of radiation therapy
and supporting a fast recovery.
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